Page last updated: 2024-12-06

oxetanocin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxetanocin A is a naturally occurring nucleoside analog that has shown potent antiviral and antitumor activities. It is known to inhibit the replication of several viruses, including HIV and hepatitis B virus. Its unique structure, featuring a four-membered oxetane ring in the sugar moiety, makes it a promising lead compound for the development of new antiviral and anticancer agents. The synthesis of oxetanocin A involves a complex multi-step process, often starting with the preparation of the oxetane ring. It is studied extensively to understand its mechanism of action and to explore potential applications for its therapeutic potential. The compound's unique structure and biological activity make it a valuable target for further research and development.'

oxetanocin: from Bacillus megaterium NK84-0218; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxetanocin A : A nucleoside analogue found in Bacillus megaterium in which an adenine moiety is attached to position 2 of a of an oxetane ring which is substituted at positions 3 and 4 by hydroxymethyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID72214
CHEMBL ID116430
CHEBI ID86012
SCHEMBL ID3417634
MeSH IDM0145499

Synonyms (24)

Synonym
9-(3,4-bis(hydroxymethyl)-2-oxetanyl)adenine
oxetanocin
9-((2r,3r,4s)-3,4-bis(hydroxymethyl)-2-oxetanyl)adenine
2,3-oxetanedimethanol, 4-(6-amino-9h-purin-9-yl)-, (2s-(2-alpha,3-beta,4-alpha))-
(-)-oxetanocin
9-[(2r,3r,4s)-3,4-bis(hydroxymethyl)-2-oxetanyl]adenine
nk 84-0218
103913-16-2
oxetanocin a
[(2r,3r,4s)-2-(6-aminopurin-9-yl)-4-(hydroxymethyl)oxetan-3-yl]methanol
2,3-oxetanedimethanol, 4-(6-amino-9h-purin-9-yl)-, [2s-(2.alpha.,3.beta.,4.alpha.)]-
chebi:86012 ,
CHEMBL116430
9-((2r, 3r, 4s)-3,4-bis-hyroxymethyl-oxetan-2-yl)-adenine
LMJVXGOFWKVXAW-OXOINMOOSA-N
9-((2r,3r,4s)-3,4-bis-hyroxymethyl-oxetan-2-yl)adenine
SCHEMBL3417634
9-((2'r,3'r,4's)-3',4'-bis(hydroxymethyl)-2'-oxetanyl)adenine
[(2s,3r,4r)-4-(6-amino-9h-purin-9-yl)oxetane-2,3-diyl]dimethanol
(-)-oxetanocin a
7D7 ,
DTXSID70146141
Q27158845
GLXC-26295

Research Excerpts

Overview

Oxetanocin A (OXT-A) is a potent antitumour, antiviral and antibacterial compound.

ExcerptReferenceRelevance
"Oxetanocin A (OXT-A) is a potent antitumour, antiviral and antibacterial compound. "( A B
Bridwell-Rabb, J; Drennan, CL; Liu, HW; Sun, HG; Zhong, A, 2017
)
1.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
oxetanesAny oxacycle that is oxetane or its substituted derivatives.
nucleoside analogueAn analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells.
primary alcoholA primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
diolA compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID106234The compound was tested for anti HIV-activity (active) against MT-4 cell line1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis.
AID82112Cytopathogenic effect was evaluated against Human immunovirus-1 (HIV-1).1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
A ring-enlarged oxetanocin A analogue as an inhibitor of HIV infectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (19.05)18.7374
1990's19 (45.24)18.2507
2000's6 (14.29)29.6817
2010's8 (19.05)24.3611
2020's1 (2.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.97 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (11.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (88.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]